Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Depreciation & Amortization (CF) (2024 - 2025)

Silence Therapeutics' Depreciation & Amortization (CF) history spans 2 years, with the latest figure at $77000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 1.32% year-over-year to $77000.0; the TTM value through Dec 2025 reached $312000.0, down 7.14%, while the annual FY2025 figure was $312000.0, 7.14% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $77000.0 at Silence Therapeutics, down from $81000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $88000.0 in Q1 2024 and bottomed at $73000.0 in Q1 2025.